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Antitumor drug sends new signals
Drugs that collapse the tumor vasculature by increasing the leakiness of 
tumor blood vessels are a new breed of chemotherapeutic agents, but 
how they worked was unknown. Now, Roberts et al. (page 1559) have 
determined the pathway and targets of one such vasculature-disrupting 
agent (VDA). They find that this drug does more than just increase leakiness.
The VDA called DMXAA works well against several types of human cancers 
and is currently in phase II clinical trials. But there are no clues from clinical 
studies to explain why this drug has succeeded where others have failed.
Experiments in mice have hinted at its downstream targets: DMXAA 
prods mouse macrophages to secrete interferon (IFN)-β and other cytokines 
that promote vessel permeability. IFN-β is also induced by activation of 
certain pattern recognition receptors (PRRs), such as the Toll-like receptors 
and the RNA helicases. But Roberts et al. now find that DMXAA’s path to 
gene induction bypasses all known PRRs. The drug instead potently activates 
the tank binding kinase (TBK)-1, leading to high levels of an activated 
transcription factor called IFN regulatory factor (IRF)-3.
Besides IFN-β, IRF-3 also turns on genes that cause the apoptosis and 
senescence of tumor cells. The functional diversity of the downstream targets 
of DMXAA might explain the high efficacy of this drug against human cancers.
Recombinant IFN-β has been used for years in the clinic to treat a 
number of malignancies including chronic myelogenous leukemia and 
malignant melanoma. Thus, Roberts et al. now tie DMXAA to this 
preeminent tumor-fighting system. 
Keeping score of 
antigraft T cells
Transplanted organs function well in their 
new home only if they are left alone by the 
host’s immune system. Now, Codarri et al. 
(page 1533) have potentially found a way to 
monitor the health of the new replace-
ments—they identify the T cells that harass 
grafts in transplant patients.
Unlike grafts that are rejected immedi-
ately, those that fail gradually are thought to 
be rejected in part by CD4+ T cells. But 
activated CD4+ T cells are difficult to distin-
guish from the regulatory T (T reg) cells that 
suppress rejection, as both express CD4 and 
CD25. Only the T reg cells also express the 
transcription factor FOXP3, but their sparse 
numbers are difficult to follow in vivo. 
FOXP3+ cells express much less IL-7Rα 
than do other CD4+ T cells. So the team 
wondered whether IL-7Rα would be a con-
venient marker to follow activated T cells 
that enter the grafts.
They now find that CD4+ CD25+ cells 
expressing high levels of IL-7Rα are abun-
dant in transplant patients. These cells infil-
trated the grafts and were able to kill donor 
cells in vitro. Patients with delayed graft 
rejection had twice as many of these cells as 
did stable transplant recipients. Both groups 
had equal numbers of T reg cells, suggest-
ing that graft rejection is caused by the in-
creased numbers of activated T cells. The 
authors are now looking at patients to de-
termine whether increases in IL-7Rα–
expressing cells can be used to predict 
transplant rejection. 
Neurons need miRNA to survive
Neurons missing their microRNA (miRNA) gradually deteriorate in 
structure and function, according to Schaefer et al. (page 1553). These 
bits of RNA prolong neuronal longevity and may keep neurodegenera-
tive diseases at bay.
miRNA—small 
pieces of RNA generated 
by the RNA-chopping 
enzyme called Dicer—
strategically shut off genes 
to allow embryonic cells 
to differentiate. Because 
mice that lack Dicer die 
as embryos, the role of 
miRNA in vivo has been 
studied by deleting Dicer 
only in specific cell types. These studies showed that Dicer—and thus 
miRNA—is required for both cell differentiation and the survival of 
some cells. Neurons need miRNA for differentiation, but whether they 
also need them for survival later was unknown.
Schaefer et al. now find that inactivating Dicer in postmitotic 
neurons of adult mice eventually kills these cells. The neurons maintained 
some of their miRNA long after Dicer inactivation and looked and 
functioned normally. But the reduction in miRNA eventually took its toll. 
Neuronal signaling malfunctioned, and the cells died off. As cell death 
progressed, the mice developed symptoms reminiscent of those seen in 
humans with neurodegenerative disorders. Whether the human disorders 
are caused by changes in specific miRNA remains to be seen. 
Activated CD4+ T cells expressing high levels of 
IL-7Rα (orange) infiltrate transplants.
Lack of Dicer causes neurons to degenerate (right).